2cvd: Difference between revisions

From Proteopedia
Jump to navigationJump to search
OCA (talk | contribs)
New page: left|200px<br /> <applet load="2cvd" size="450" color="white" frame="true" align="right" spinBox="true" caption="2cvd, resolution 1.45Å" /> '''Crystal structure a...
 
OCA (talk | contribs)
No edit summary
Line 1: Line 1:
[[Image:2cvd.gif|left|200px]]<br />
[[Image:2cvd.gif|left|200px]]<br /><applet load="2cvd" size="350" color="white" frame="true" align="right" spinBox="true"  
<applet load="2cvd" size="450" color="white" frame="true" align="right" spinBox="true"  
caption="2cvd, resolution 1.45&Aring;" />
caption="2cvd, resolution 1.45&Aring;" />
'''Crystal structure analysis of human hematopoietic prostaglandin D synthase complexed with HQL-79'''<br />
'''Crystal structure analysis of human hematopoietic prostaglandin D synthase complexed with HQL-79'''<br />


==Overview==
==Overview==
We determined the crystal structure of human hematopoietic prostaglandin, (PG) D synthase (H-PGDS) as the quaternary complex with glutathione (GSH), Mg2+, and an inhibitor, HQL-79, having anti-inflammatory activities in, vivo, at a 1.45-A resolution. In the quaternary complex, HQL-79 was found, to reside within the catalytic cleft between Trp104 and GSH. HQL-79 was, stabilized by interaction of a phenyl ring of its diphenyl group with, Trp104 and by its piperidine group with GSH and Arg14 through water, molecules, which form a network with hydrogen bonding and salt bridges, linked to Mg2+. HQL-79 inhibited human H-PGDS competitively against the, substrate PGH2 and non-competitively against GSH with Ki of 5 and 3, microm, respectively. Surface plasmon resonance analysis revealed that, HQL-79 bound to H-PGDS with an affinity that was 12-fold higher in the, presence of GSH and Mg2+ (Kd, 0.8 microm) than in their absence., Mutational studies revealed that Arg14 was important for the Mg2+-mediated, increase in the binding affinity of H-PGDS for HQL-79, and that Trp104, Lys112, and Lys198 were important for maintaining the HQL-binding pocket., HQL-79 selectively inhibited PGD2 production by H-PGDS-expressing human, megakaryocytes and rat mastocytoma cells with an IC50 value of about 100, microm but only marginally affected the production of other prostanoids, suggesting the tight functional engagement between H-PGDS and, cyclooxygenase. Orally administered HQL-79 (30 mg/kg body weight), inhibited antigen-induced production of PGD2, without affecting the, production of PGE2 and PGF2alpha, and ameliorated airway inflammation in, wild-type and human H-PGDS-overexpressing mice. Knowledge about this, structure of quaternary complex is useful for understanding the inhibitory, mechanism of HQL-79 and should accelerate the structure-based development, of novel anti-inflammatory drugs that inhibit PGD2 production, specifically.
We determined the crystal structure of human hematopoietic prostaglandin (PG) D synthase (H-PGDS) as the quaternary complex with glutathione (GSH), Mg2+, and an inhibitor, HQL-79, having anti-inflammatory activities in vivo, at a 1.45-A resolution. In the quaternary complex, HQL-79 was found to reside within the catalytic cleft between Trp104 and GSH. HQL-79 was stabilized by interaction of a phenyl ring of its diphenyl group with Trp104 and by its piperidine group with GSH and Arg14 through water molecules, which form a network with hydrogen bonding and salt bridges linked to Mg2+. HQL-79 inhibited human H-PGDS competitively against the substrate PGH2 and non-competitively against GSH with Ki of 5 and 3 microm, respectively. Surface plasmon resonance analysis revealed that HQL-79 bound to H-PGDS with an affinity that was 12-fold higher in the presence of GSH and Mg2+ (Kd, 0.8 microm) than in their absence. Mutational studies revealed that Arg14 was important for the Mg2+-mediated increase in the binding affinity of H-PGDS for HQL-79, and that Trp104, Lys112, and Lys198 were important for maintaining the HQL-binding pocket. HQL-79 selectively inhibited PGD2 production by H-PGDS-expressing human megakaryocytes and rat mastocytoma cells with an IC50 value of about 100 microm but only marginally affected the production of other prostanoids, suggesting the tight functional engagement between H-PGDS and cyclooxygenase. Orally administered HQL-79 (30 mg/kg body weight) inhibited antigen-induced production of PGD2, without affecting the production of PGE2 and PGF2alpha, and ameliorated airway inflammation in wild-type and human H-PGDS-overexpressing mice. Knowledge about this structure of quaternary complex is useful for understanding the inhibitory mechanism of HQL-79 and should accelerate the structure-based development of novel anti-inflammatory drugs that inhibit PGD2 production specifically.


==About this Structure==
==About this Structure==
2CVD is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] with MG, GSH, HQL and GOL as [http://en.wikipedia.org/wiki/ligands ligands]. Full crystallographic information is available from [http://ispc.weizmann.ac.il/oca-bin/ocashort?id=2CVD OCA].  
2CVD is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] with <scene name='pdbligand=MG:'>MG</scene>, <scene name='pdbligand=GSH:'>GSH</scene>, <scene name='pdbligand=HQL:'>HQL</scene> and <scene name='pdbligand=GOL:'>GOL</scene> as [http://en.wikipedia.org/wiki/ligands ligands]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2CVD OCA].  


==Reference==
==Reference==
Line 26: Line 25:
[[Category: isomerase]]
[[Category: isomerase]]


''Page seeded by [http://ispc.weizmann.ac.il/oca OCA ] on Mon Nov 12 21:24:22 2007''
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 16:52:52 2008''